Base de dados : MEDLINE
Pesquisa : C04.557.450.565.370 [Categoria DeCS]
Referências encontradas : 5341 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 535 ir para página                         

  1 / 5341 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29489686
[Au] Autor:Shi X; Yu S; Wang F; Zhao Q; Xu H; Li B
[Ad] Endereço:Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University.
[Ti] Título:A gastrointestinal stromal tumor with acute bleeding: Management and nursing.
[So] Source:Medicine (Baltimore);97(9):e9874, 2018 Mar.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors involving the gastrointestinal tract. A small percentage of GISTs may cause acute gastrointestinal bleeding, which requires urgent surgical intervention. PATIENT CONCERNS: In this case report, we present a 62-year-old male patient with who was hospitalized due to acute bleeding. DIAGNOSES: The patient was diagnosed as GIST with low risk. INTERVENTIONS: The patient was treated endoscopically with polidocanol sclerotherapy. OUTCOMES: The mass was removed completely, and the patient was discharged at day 9 after operation. LESSONS: This case indicates that GIST can present as massive upper gastrointestinal bleeding and urgent endoscopic sclerotherapy can be life-saving. The endoscopical intervention may be a good alternative for emergency.
[Mh] Termos MeSH primário: Hemorragia Gastrointestinal/etiologia
Neoplasias Gastrointestinais/complicações
Tumores do Estroma Gastrointestinal/complicações
[Mh] Termos MeSH secundário: Hemorragia Gastrointestinal/terapia
Neoplasias Gastrointestinais/terapia
Tumores do Estroma Gastrointestinal/terapia
Seres Humanos
Masculino
Meia-Idade
Polietilenoglicóis/uso terapêutico
Soluções Esclerosantes/uso terapêutico
Escleroterapia/métodos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Sclerosing Solutions); 0AWH8BFG9A (polidocanol); 30IQX730WE (Polyethylene Glycols)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180301
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009874


  2 / 5341 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29480823
[Au] Autor:Qiu HB; Zhou ZG; Feng XY; Liu XC; Guo J; Ma MZ; Chen YB; Sun XW; Zhou ZW
[Ad] Endereço:Department of Gastric and Pancreatic Surgery.
[Ti] Título:Advanced gastrointestinal stromal tumor patients benefit from palliative surgery after tyrosine kinase inhibitors therapy.
[So] Source:Medicine (Baltimore);97(2):e9097, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The role of palliative surgery is controversial in advanced gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitors (TKIs) therapy.We evaluated safety and clinical outcomes in a single institution series of advanced GIST patients from January 2002 to December 2008.One hundred and fifty-six patients had been recruited, including 87 patients underwent surgical resection and 69 patients kept on TKIs treatment. Four patients had major surgical complications. Median follow-up was 38.3 months, the overall survival (OS) and progression-free survival (PFS) of the patients in surgical group were longer than the nonsurgical group, PFS: 46.1 versus 33.8 months (P < .01), OS: 54.8 versus 40.4 months. In the subgroup analysis for the patients received surgery, the median PFS for patients with progression disease, stable disease, and partial response was 33.3, 51.5, and 83.0 months, respectively (P < .01). Median OS was 68.0 months in those with only liver or peritoneal metastases, and 45.3 months in those with both metastases. Median PFS of patients underwent R0/R1 resection was 73.6 months compared with 35.8 months in R2 resection patients (P < .01).Patients with advanced GISTs have prolonged OS after debulking procedures. Surgery for patients who have responsive disease after TKIs treatment should be considered.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Tumores do Estroma Gastrointestinal/tratamento farmacológico
Tumores do Estroma Gastrointestinal/cirurgia
Cuidados Paliativos
Inibidores de Proteínas Quinases/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Intervalo Livre de Doença
Feminino
Seguimentos
Tumores do Estroma Gastrointestinal/mortalidade
Tumores do Estroma Gastrointestinal/patologia
Seres Humanos
Mesilato de Imatinib/uso terapêutico
Neoplasias Hepáticas/mortalidade
Neoplasias Hepáticas/secundário
Masculino
Meia-Idade
Neoplasias Peritoneais/mortalidade
Neoplasias Peritoneais/secundário
Proteínas Tirosina Quinases/antagonistas & inibidores
Estudos Retrospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Protein Kinase Inhibitors); 8A1O1M485B (Imatinib Mesylate); EC 2.7.10.1 (Protein-Tyrosine Kinases)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180227
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009097


  3 / 5341 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29424982
[Au] Autor:Fernández­Ruiz M; Cabezas­Palacios MN; Rodríguez­Zarco E; Tato­Varela S
[Ti] Título:[Gatrointestinal stromal tumor: a case report].
[Ti] Título:Tumor del estroma gastrointestinal: reporte de un caso..
[So] Source:Ginecol Obstet Mex;84(9):607-13, 2016 Sep.
[Is] ISSN:0300-9041
[Cp] País de publicação:Mexico
[La] Idioma:spa
[Ab] Resumo:Gastrointestinal stromal tumors are the most common mesenquimal neoplasms of the gastrointestinal tract. A preoperative diagnose of GIST it is very difficult to make, but up to 5% of the cases initially appear as a pelvic mass. Clinical case: 45-year-old patient attended in medical service by unspecific pain in the lower abdomen of several weeks of evolution. The abdominopelvic tomography evidence collection of 9×8 cm above of the uterus and sigma's right with air in the cavity, it is was compatible with pelvic abscess. Due to increased pain, we realized emergency exploratory laparotomy, which showed a 14 cm tumor, dependent of the small intestine, without ascites or involvement other organs of the digestive or reproductive tract. The excision of the tumor was successfully (non intraoperative rupture). The pathological study reported a bowel piece of 20 cm, in which a tumor of 14 cm with large central cavitation was identified. Histologically showed diffuse growth pattern and neoplastic epithelioid cells with low rate of mitosis (mitosis 1-2/5 mm2). The immunohistochemistry test reports strong expression of DOG-1 and focal expression in CD117 (c-kit), with very low proliferation index (Ki67). The molecular pathology study identified a mutation in exon 11, codon 557-558, the c-kit gene in the p.W557_K558del position. We use imatinib (400 mg/24 h) from the second month after surgery. Today keep in treatment, and clinical and laboratories following every month: in addition, to CT scans scheduled every 6 months.
[Mh] Termos MeSH primário: Dor Abdominal/etiologia
Neoplasias Gastrointestinais/diagnóstico
Tumores do Estroma Gastrointestinal/diagnóstico
[Mh] Termos MeSH secundário: Feminino
Neoplasias Gastrointestinais/patologia
Neoplasias Gastrointestinais/cirurgia
Tumores do Estroma Gastrointestinal/patologia
Tumores do Estroma Gastrointestinal/cirurgia
Seres Humanos
Mesilato de Imatinib/administração & dosagem
Laparotomia/métodos
Meia-Idade
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
8A1O1M485B (Imatinib Mesylate)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180210
[St] Status:MEDLINE


  4 / 5341 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29284772
[Au] Autor:Patial T; Sharma K; Thakur D; Gupta G
[Ad] Endereço:Department of General Surgery, Indira Gandhi Medical College, Shimla, Himachal Pradesh 171001, India.
[Ti] Título:Consumptive hypothyroidism: an unusual paraneoplastic manifestation of a gastric gastrointestinal stromal tumor.
[So] Source:Exp Oncol;39(4):319-321, 2017 Dec.
[Is] ISSN:1812-9269
[Cp] País de publicação:Ukraine
[La] Idioma:eng
[Ab] Resumo:A 42-year-old hypothyroid shepherd presented with a progressive abdominal lump accompanied by nausea and abdominal fullness. In addition, he had worsening hypothyroidism, despite supranormal doses of thyroxine. Computed tomography of the abdomen was suggestive of a mass lesion in relation to the stomach. A resection of the mass was done and the histopathology was suggestive of gastrointestinal stromal tumor. After surgery, the patient became euthyroid. We believe the patient had consumptive hypothyroidism due to the tumor.
[Mh] Termos MeSH primário: Tumores do Estroma Gastrointestinal/complicações
Tumores do Estroma Gastrointestinal/patologia
Hipotireoidismo/etiologia
Síndromes Paraneoplásicas/etiologia
[Mh] Termos MeSH secundário: Adulto
Seres Humanos
Hipotireoidismo/patologia
Masculino
Síndromes Paraneoplásicas/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171230
[St] Status:MEDLINE


  5 / 5341 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29443783
[Au] Autor:Matsuo K; Inoue M; Shirai Y; Kataoka T; Kagota S; Taniguchi K; Lee SW; Uchiyama K
[Ad] Endereço:Department of General and Gastroenterological Surgery, Osaka Medical College, Daigakumachi, Takatsuki.
[Ti] Título:Giant GIST of the stomach: a successful case of safe resection with preoperative simulation using three-dimensional CT angiography: Case report.
[So] Source:Medicine (Baltimore);97(7):e9945, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: We report a very rare case of safely resectable giant gastrointestinal stromal tumor (GIST) with preoperative three-dimensional computed tomography (3D-CT) angiography in spite of no neoadjuvant treatment. PATIENT'S CONCERN: A 71-year-old woman presented to our hospital with an abdominal giant tumor. As this giant tumor could not be accurately diagnosed by preoperative investigation, we had to perform her surgical treatment without neoadjuvant treatment. However, preoperative 3D-CT angiography clearly showed that the tumor was supplied by the right gastroepiploic artery (RGA). Based on the preoperative information, a surgical procedure was undertaken. DIAGNOSIS: Giant tumor of stomach with suspicion of GIST. INTERVENTIONS: Laparotomy guided by 3D-CT imaging including angiography. OUTCOME: The giant tumor originated from the greater curvature of the distal stomach and was supplied by the RGA, as expected. The tumor was resected easily under the accurate preoperative anatomical information. The tumor measured 20 cm × 20 cm in size and weighed 2500 g (Fig. 2C and D). Histopathological examination showed evidence of growth of spindle-shaped cells and a low mitotic index (3 per 50 high-power field, Fig. 3B). Immunohistochemical examination showed positive immunoreactions for KIT, CD34, and DOG1 (Fig. 3 C-E), but negative ones for SMA and S-100 protein (Fig. 3F and G). Consequently, we made a final diagnosis of an extra luminal GIST of the stomach. The post-operative course was uneventful, and so the patient was discharged on postoperative day 13. LESSONS: Making full use of an imaging procedure such as 3D-CT angiography is one of the effective tools for the surgical management of giant-size tumors including giant GISTs.
[Mh] Termos MeSH primário: Angiografia por Tomografia Computadorizada
Tumores do Estroma Gastrointestinal/diagnóstico por imagem
Tumores do Estroma Gastrointestinal/cirurgia
Imagem Tridimensional
Neoplasias Gástricas/diagnóstico por imagem
Neoplasias Gástricas/cirurgia
[Mh] Termos MeSH secundário: Idoso
Feminino
Tumores do Estroma Gastrointestinal/patologia
Seres Humanos
Neoplasias Gástricas/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180215
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009945


  6 / 5341 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29443772
[Au] Autor:Yang J
[Ti] Título:Primary leiomyosarcoma in the colon: A case report.
[So] Source:Medicine (Baltimore);97(7):e9923, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Leiomyosarcoma (LMS) is a common type of soft tissue sarcoma. Primary colonic LMS in general is a very rare entity, accounting for 1% to 2% of gastrointestinal malignancies. PATIENT CONCERNS: We report a case of 55-year-old female who presented with a sudden onset of sharp right lower quadrant abdominal pain. Electronic colonoscopy showed a normal lumen. However, an abdominal computed tomography scan revealed a mass of soft tissue attenuation inseparable from the ascending colon which appeared as a gastrointestinal stromal tumor (GIST). DIAGNOSES: It is important to diagnose LMS definitively by immunohistochemical profiling of smooth muscle actin, desmin, and CD34. INTERVENTIONS: She underwent laparotomy and right hemicolectomy, and histology confirmed a colonic LMS. The patient received no oncological treatment after surgery. OUTCOMES: No recurrence or metastasis was observed at 5 months postoperatively. It is crucial to identify colonic LMS precisely based on immunohistochemistry, and thereby distinguish it from GIST. LESSONS: Further investigation on LMS cases so far is required to establish standard treatment strategies.
[Mh] Termos MeSH primário: Neoplasias do Colo/diagnóstico
Leiomiossarcoma/diagnóstico
[Mh] Termos MeSH secundário: Colectomia
Neoplasias do Colo/diagnóstico por imagem
Neoplasias do Colo/cirurgia
Colonoscopia
Diagnóstico Diferencial
Feminino
Tumores do Estroma Gastrointestinal/diagnóstico
Seres Humanos
Imuno-Histoquímica
Leiomiossarcoma/diagnóstico por imagem
Leiomiossarcoma/cirurgia
Meia-Idade
Tomografia Computadorizada por Raios X
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180215
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009923


  7 / 5341 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29382014
[Au] Autor:Li BJ; Yang XD; Chen WX; Shi YH; Nie ZH; Wu J
[Ad] Endereço:Department of Gastroenterology.
[Ti] Título:Calcifying fibrous tumor of stomach: A case report.
[So] Source:Medicine (Baltimore);96(47):e8882, 2017 Nov.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Calcifying fibrous tumor (CFT) is a rare benign soft tissue mesenchymal neoplasm. Although the gastrointestinal (GI) tract is the most common predilection site of CFT, the clinicians, even including pathologist, generally consider it as GI stromal tumor (GIST) or other submucosal tumors such as schwannoma and leiomyoma. PATIENT CONCERNS: A 55-year-old man presented with complaints of epigastric discomfort and abdominal distention for more than 1 year. DIAGNOSES: On the basis of endoscopic and computed tomography examination, preliminary diagnosis was GIST. INTERVENTIONS: Endoscopic submucosal dissection (ESD) surgery was performed to remove the gastric mass. OUTCOMES: The histopathological examination revealed a gastric CFT. LESSONS: We present a case of gastric CFT, which was misdiagnosed as GIST based on endoscopic and radiologic findings.
[Mh] Termos MeSH primário: Calcinose/diagnóstico
Erros de Diagnóstico
Neoplasias de Tecido Fibroso/diagnóstico
Neoplasias Gástricas/diagnóstico
[Mh] Termos MeSH secundário: Calcinose/patologia
Diagnóstico Diferencial
Neoplasias Gastrointestinais/diagnóstico
Tumores do Estroma Gastrointestinal/diagnóstico
Seres Humanos
Masculino
Meia-Idade
Neoplasias de Tecido Fibroso/patologia
Neoplasias Gástricas/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180207
[Lr] Data última revisão:
180207
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008882


  8 / 5341 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27777072
[Au] Autor:Bahlawane C; Schmitz M; Letellier E; Arumugam K; Nicot N; Nazarov PV; Haan S
[Ad] Endereço:Molecular Disease Mechanisms group, Life Sciences Research Unit, University of Luxembourg, Campus Belval, 6 Avenue du Swing, L-4367 Belvaux, Luxembourg. Electronic address: christelle.bahlawane@uni.lu.
[Ti] Título:Insights into ligand stimulation effects on gastro-intestinal stromal tumors signalling.
[So] Source:Cell Signal;29:138-149, 2017 01.
[Is] ISSN:1873-3913
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Mutations in KIT or PDGFRA are responsible for >85% of gastrointestinal stromal tumors. The introduction of imatinib in the GIST therapy scheme revolutionized the patient outcome. Unfortunately, the therapy allows the disease stabilization instead of curation. Furthermore the resistance to the inhibitor arises in most cases within two first years of therapy. A thorough investigation of the signalling pathways activated by the major PDGFRA and KIT mutants encountered in the GIST landscape allowed to identify striking differences between the two receptor tyrosine kinases. PDGFRA mutants were not responsive to their ligand, PDGFAA, and displayed a high constitutive kinase activity. In contrast, all KIT mutants retained, in addition to their constitutive activation, the ability to be stimulated by their ligand. Kit mutants displayed a lower intrinsic kinase activity relative to PDGFRA mutants, while the KIT Exon 11 deletion mutant exhibited the highest intrinsic kinase activity among KIT mutants. At the transcriptomic level, the MAPK pathway was established as the most prominent activated pathway, which is commonly up-regulated by all PDGFRA and KIT mutants. Inhibition of this pathway, using the MEK inhibitor PD0325901, reduced the proliferation of GIST primary cells at nanomolar concentrations. Altogether, our data demonstrate the high value of MEK inhibitors for combination therapy in GIST treatment and more importantly the interest of evaluating the SCF expression profile in GIST patients presenting KIT mutations.
[Mh] Termos MeSH primário: Tumores do Estroma Gastrointestinal/metabolismo
Tumores do Estroma Gastrointestinal/patologia
Transdução de Sinais
[Mh] Termos MeSH secundário: Biomarcadores Tumorais/metabolismo
Linhagem Celular Tumoral
Tumores do Estroma Gastrointestinal/genética
Perfilação da Expressão Gênica
Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos
Células HEK293
Seres Humanos
Ligantes
Sistema de Sinalização das MAP Quinases/efeitos dos fármacos
Simulação de Dinâmica Molecular
Mutação/genética
Inibidores de Proteínas Quinases/farmacologia
Transporte Proteico
Proteínas Proto-Oncogênicas c-kit/metabolismo
Receptor alfa de Fator de Crescimento Derivado de Plaquetas/metabolismo
Transdução de Sinais/efeitos dos fármacos
Regulação para Cima/efeitos dos fármacos
Regulação para Cima/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Ligands); 0 (Protein Kinase Inhibitors); EC 2.7.10.1 (Proto-Oncogene Proteins c-kit); EC 2.7.10.1 (Receptor, Platelet-Derived Growth Factor alpha)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:180124
[Lr] Data última revisão:
180124
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161107
[St] Status:MEDLINE


  9 / 5341 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29310354
[Au] Autor:Chu Y; Guo Q; Wu D
[Ad] Endereço:Department of Surgery, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang, P.R. China.
[Ti] Título:Mesenteric fibromatosis after resection for gastrointestinal stromal tumor of stomach: A case report.
[So] Source:Medicine (Baltimore);96(48):e8792, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Gastrointestinal stromal tumor and mesenteric fibromatosis are rare mesenchymal tumors. Coexistence of these two diseases is uncommon, with only a few anecdotal reports of individuals. PATIENT CONCERNS: Clinical data and treatment of a 43-year-old man with subsequent mesenteric fibromatosis from gastrointestinal stromal tumor are summarized. The Ethics Committee of The Second Affiliated Hospital, College of Medicine, Zhejiang University approved this study, and the patient provided written informed consent form. DIAGNOSES: The initial diagnosis of the recurrent mesenteric mass was recurrent gastrointestinal stromal tumor. INTERVENTIONS: The operation was performed as possible at the time when the mass was found after the first surgery. OUTCOMES: The diagnosis was revised as mesenteric fibromatosis according to the postoperative immunohistochemical staining. The postoperative condition was normal without adjuvant therapy and no recidivation has been found. LESSONS: The potential for the coexistence of gastrointestinal stromal tumor and mesenteric fibromatosis should always be considered.
[Mh] Termos MeSH primário: Fibromatose Abdominal/patologia
Tumores do Estroma Gastrointestinal/patologia
Neoplasias Primárias Múltiplas/patologia
[Mh] Termos MeSH secundário: Adulto
Diagnóstico por Imagem
Fibromatose Abdominal/diagnóstico
Fibromatose Abdominal/cirurgia
Tumores do Estroma Gastrointestinal/cirurgia
Gastroscopia
Seres Humanos
Imuno-Histoquímica
Masculino
Neoplasias Primárias Múltiplas/diagnóstico
Neoplasias Primárias Múltiplas/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180115
[Lr] Data última revisão:
180115
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180110
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008792


  10 / 5341 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29310342
[Au] Autor:Zhang Z; Jiang T; Wang W; Piao D
[Ad] Endereço:Department of Colorectal Surgery, The First Affiliated Hospital of Harbin Medical University.
[Ti] Título:Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis.
[So] Source:Medicine (Baltimore);96(48):e8698, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:AIMS: This meta-analysis aimed to evaluate the safety and efficacy of regorafenib as a treatment for patients with advanced (metastatic and/or unresectable) gastrointestinal stromal tumor (AGIST) after developing resistance to imatinib and sunitinib. METHODS: A literature search of databases such as PubMed, Embase, and Cochrane library was conducted up to February 2017. The pooled percentages and the corresponding 95% confidence intervals (CIs) were calculated using the Stata 11.0 software. RESULTS: Four studies involving 243 patients with AGIST were included. Results revealed that approximately 49% (95% CI 30-67), 14% (95% CI 5-23), and 41% (95% CI 21-61) of patients with AGIST showed clinical benefit (including complete response), partial response, and stable disease, respectively, after regorafenib treatment, which was given after failure with imatinib and sunitinib treatments. No complete response was found in the included studies. Pooled progression-free survival was 6.58 months (95% CI 4.62-8.54). Hypertension (20%; 95% CI 7-33), hand-foot skin reaction (22%; 95% CI 17-27), and hypophosphatemia (18%; 95% CI 5-41) were common grade ≥3 regorafenib-related adverse events in patients treated with regorafenib after failure with imatinib and sunitinib treatments. CONCLUSIONS: Forty-nine per cent of patients with AGIST benefited after regorafenib treatment after the development of resistance to imatinib and sunitinib. More studies should be performed to improve the clinical survival of patients with AGIST. Close monitoring and appropriate management of grade ≥3 regorafenib-related adverse events should be considered during treatment.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Resistência a Medicamentos Antineoplásicos
Tumores do Estroma Gastrointestinal/tratamento farmacológico
Compostos de Fenilureia/uso terapêutico
Piridinas/uso terapêutico
[Mh] Termos MeSH secundário: Tumores do Estroma Gastrointestinal/patologia
Seres Humanos
Mesilato de Imatinib/uso terapêutico
Indóis/uso terapêutico
Pirróis/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Indoles); 0 (Phenylurea Compounds); 0 (Pyridines); 0 (Pyrroles); 24T2A1DOYB (regorafenib); 8A1O1M485B (Imatinib Mesylate); V99T50803M (sunitinib)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180115
[Lr] Data última revisão:
180115
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180110
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008698



página 1 de 535 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde